Skip to main content
SyntekaBio,Inc. logo

SyntekaBio,Inc. — Investor Relations & Filings

Ticker · 226330 ISIN · KR7226330009 KO Professional, scientific and technical activities
Open in API
Filings indexed 322 across all filing types
Latest filing 2026-05-18 Major Shareholding Noti…
Country KR South Korea
Listing KO 226330

About SyntekaBio,Inc.

https://www.syntekabio.com/

SyntekaBio is an AI-driven drug discovery company that utilizes its proprietary supercomputing infrastructure, the AI Bio-Supercom Center, to accelerate pharmaceutical development. The company's core technology, the DeepMatcher® platform, underpins a suite of services for discovering small molecules, antibodies, and neoantigens for personalized cancer vaccines. A key offering is LaunchPad, a factory-like system that continuously generates a stream of 'off-the-shelf' drug candidates for numerous disease targets, aiming to expedite the path to IND-enabling studies. SyntekaBio delivers its solutions through comprehensive discovery partnerships and a modular, cloud-based Software as a Service (SaaS) platform, STB CLOUD, providing researchers with automated tools for drug development and genomics analysis.

Recent filings

Filing Released Lang Actions
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 95% confidence The document is a ‘주식등의 대량보유상황보고서’ (Large Shareholding Status Report) filed under Korea’s Capital Markets Act, detailing a major shareholder’s holding levels, changes, and related contractual arrangements. This aligns with our “Major Shareholding Notification” category, Code: MRQ.
2026-05-18 Korean
임원ㆍ주요주주특정증권등소유상황보고서
Director's Dealing Classification · 95% confidence The document is a statutory Korean insider trading report titled “임원ㆍ주요주주 특정증권등 소유상황보고서,” detailing the purchase of shares by an executive (정종선) of Syntekabio, including share counts, transaction dates, and ownership percentages, submitted to the Securities and Futures Commission and the Korea Exchange. This matches the description for a Director’s Dealing (insider share transaction) report.
2026-05-18 Korean
분기보고서 (2026.03)
Interim / Quarterly Report Classification · 98% confidence The document clearly presents itself as a Korean "분기보고서" (quarterly report) for the period January 1 to March 31, 2026, filed with the Financial Services Commission and Korea Exchange, and includes comprehensive company overview, corporate history, capital changes, and presumably detailed financial statements and analyses. This matches the definition of an Interim/Quarterly Report. Q1 2026
2026-05-15 Korean
주식매수선택권부여에관한신고
Regulatory Filings Classification · 85% confidence The document is a regulatory disclosure in Korean titled “Report on grant of stock options” (주식매수선택권 부여에 관한 신고) filed with the Financial Supervisory Service/KRX. It details the terms of a stock‐option grant (number of options, exercise price calculations, conditions, fair value assumptions), but is not an earnings release, financial report, management change notice, or director insider trade. It is a specific corporate regulatory filing that doesn’t match one of the more narrowly defined categories, so it falls under the general “Regulatory Filings” fallback.
2026-05-15 Korean
전환사채(해외전환사채포함)발행후만기전사채취득
Capital/Financing Update Classification · 95% confidence The document details the acquisition of convertible bonds (including overseas convertible bonds) before maturity, specifying issuance dates, amounts, acquisition reasons, and future handling methods. It includes financial figures related to bond acquisition and references to related disclosures. This is an update on the company's capital structure and financing activities, specifically about bond issuance and repurchase. The document is short (1818 characters) and focused on a specific financing event rather than a full financial report or announcement of a report. Therefore, it fits best under Capital/Financing Update (CAP).
2026-05-08 Korean
[기재정정]투자판단관련주요경영사항 (AbARS™플랫폼으로 발굴한 항암 및 면역질환 항체 후보물질 기술이전)
Regulatory Filings Classification · 72% confidence The document is a short regulatory disclosure (2540 characters) in Korean titled “투자판단 관련 주요경영사항” announcing a technology‐transfer contract correction and receipt of payment. It is not an AGM presentation, annual/interim report, earnings release, call transcript, M&A activity, capital‐raising, share issue, dividend notice, board change, or any other specific category. Thus it falls into the general regulatory filings fallback category.
2026-04-10 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.